AAS
ALGS icon

Avantax Advisory Services’s Aligos Therapeutics ALGS Stock Holding History

Avantax Advisory Services’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,570
Closed -$1.22M – 2233
2024
Q4 		$1.22M Buy
+30,570
New +$591K 0.01% 950

Other funds holding ALGS

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avantax Advisory Services's ALGS Position: Q1 2025 in Review

Avantax Advisory Services sold out of Aligos Therapeutics (ALGS) in Q1 2025, closing a stake of 30,570 shares — an estimated $1.22M sold.

Avantax Advisory Services first reported a position in ALGS in Q4 2024 and held it in 1 quarter. The position peaked at $1.22M in Q4 2024. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2025.

  • Avantax Advisory Services reported no remaining Aligos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Avantax Advisory Services sold 30,570 Aligos Therapeutics shares in Q1 2025, an estimated $1.22M.
  • Avantax Advisory Services first reported a position in Aligos Therapeutics in Q4 2024 and held it in 1 quarter.
  • Avantax Advisory Services's Aligos Therapeutics position peaked at $1.22M in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2025.

Based on Avantax Advisory Services's 13F filing for Q1 2025, filed 6 May 2025.